Home About us Contact | |||
New Indication (new + indication)
Selected AbstractsTreatment before Seizures: New Indications for Antiepileptic Therapy in Children with Tuberous Sclerosis ComplexEPILEPSIA, Issue 8 2007Sergiusz Józwiak No abstract is available for this article. [source] Abdominal compartment syndrome: a new indication for operative intervention in severe acute pancreatitisINTERNATIONAL JOURNAL OF CLINICAL PRACTICE, Issue 12 2005K. Wong Summary The current management of severe acute pancreatitis (SAP) is maximal conservative therapy within an intensive care environment. The only commonly accepted indication for operative intervention is the presence of infected pancreatic necrosis. We present a case wherein a laparotomy performed for treatment of abdominal compartment syndrome (ACS) arising in the setting of SAP in the absence of pancreatic necrosis prevented early mortality and discuss the diagnosis and treatment of ACS as a new indication for operative intervention in SAP. [source] Statins for non-alcoholic fatty liver disease: a new indication?ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 4 2006E. N. Liberopoulos No abstract is available for this article. [source] A new indication for liver transplantation: Nodular regenerative hyperplasia in human immunodeficiency virus,infected patientsLIVER TRANSPLANTATION, Issue 8 2008Mariagrazia Tateo Nodular regenerative hyperplasia is one of the causes of noncirrhotic portal hypertension and has recently been described in human immunodeficiency virus,infected patients, and the potential role of a prothrombotic state and hepatotoxic antiretroviral medication has been suggested. Moreover, it is now established that liver transplantation is feasible in HIV-infected patients. We describe here our experience concerning 3 HIV-infected patients with severe complications of nodular regenerative hyperplasia treated with liver transplantation. Liver Transpl 14:1194,1198, 2008. © 2008 AASLD. [source] Novel pharmacological approaches in the treatment of psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Issue 1 2005V Schleyer ABSTRACT Progress in the understanding of psoriasis as a T-cell mediated inflammatory disease has led to the development of new immunomodulatory therapies. Currently the main focus is on the so-called biologics (or biological agents), including fusion proteins, monoclonal antibodies, cytokines and selective receptors. They mainly target single steps in the complex cascade of humoral and cellular inflammatory immunomechanisms that finally lead to the accelerated growth of epidermal and vascular cells in the psoriatic lesions. The most promising and advanced biological agents are discussed along with their influence on the critical pathophysiological steps in psoriasis, including depletion of T cells, blockade of initial T-cell activation and T-cell receptor (TCR) stimulation, blockade of costimulatory signals and T-cell proliferative signals as well as restoration of the T helper type 1 (Th1)/Th2 balance by diminishing type 1 cytokines and administration of type 2 cytokines. In addition to the biological agents, further development of ,classical' dermatological therapies, such as retinoids, or the discovery of new indications for non-dermatological agents contribute to the novel pharmacological approaches in the treatment of psoriasis. [source] Sublingual immunotherapy in the treatment of childrenALLERGY, Issue 2006N. Pham-Thi Children with controlled intermittent mild-to-moderate asthma, controlled rhinitis and a single sensitivity may be appropriate candidates for sublingual immunotherapy (SLIT). Positive effects of SLIT may depend on initiation in early childhood and a long duration of treatment. To ensure optimum compliance, sociological, economic and familial factors should also be taken in to consideration when prescribing SLIT. Evidence from recent long-term trials indicates that SLIT interfered with the atopic march and the allergic progression from rhinitis to asthma without any severe adverse side effects. Local immune response has been seen to be blunted with SLIT, which suggests that treatment has an immunomodulatory effect. In addition, it may also decrease the risk of new sensitizations. Ongoing developments in SLIT, particularly advances in dosing and new indications, such as food allergies, will increase the use of this treatment modality in children. [source] |